Atezolizumab for Idiopathic Pulmonary Fibrosis
Atezolizumab for Idiopathic Pulmonary Fibrosis
Active, not recruiting · NCT05515627 · Registry updated 2026-02-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atezolizumab for Idiopathic Pulmonary Fibrosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 1 | 2026-02-20 | NCT05515627 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cedars-Sinai Medical Center | 161 |
| Genentech, Inc. | 221 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |